Azacitidine

Plasmacytoma of Bone

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the Plasmacytoma of Bone cohort.

Asset / Sponsor	Phase	Rating
Thalidomide Margarida Magalhaes-Silverman	Phase 2	B
TACROLIMUS Fred Hutchinson Cancer Center	Phase 2	B
DEXAMETHASONE Memorial Sloan Kettering Cancer Center	Phase 2	B
PROPADERM FORTE Fred Hutchinson Cancer Center	Phase 2	B
METHOTREXATE Fred Hutchinson Cancer Center	Phase 2	B

View all 19 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

73 / 100

acute erythroid leukemiaDormant

BB

Indicative ·

71 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.